Torrent Pharmaceuticals Share Price

NSE: TORNTPHARM
|
Pharmaceuticals

â‚ą 4,580.00

-â‚ą62.90 (-1.35%)
1D
Last updated 14 Oct, 2026, 15:53 IST

Torrent Pharmaceuticals Share Price Today

As of 15 Oct 2026, Torrent Pharmaceuticals share price is â‚ą4,580.00. The stock opened at â‚ą4,640.00, compared to its previous close of â‚ą4,642.90. During today's trading session, Torrent Pharmaceuticals share price moved in the range of â‚ą4,551.80 to â‚ą4,640.00, with an average price of â‚ą4,595.90 for the day. Looking at its last 52-week, the stock has touched a low of â‚ą3,480.60 and a high of â‚ą5,250.00. On the performance front, Torrent Pharmaceuticals share price has increased by 9.54% over the last six months and is up 30.04% on a year-on-year basis.

â‚ą4,551.80
1.35% down today
â‚ą4,640.00
1D LOW
1D HIGH

Torrent Pharmaceuticals Returns Calculator

Volume
3,13,952
Average traded price
â‚ą4,584.65
Last traded time
03:53:12 14 Oct
Last traded quantity
1
Circuit
L
H
â‚ą4,438.00
â‚ą4,712.40
52-week
L
H
â‚ą3,480.60
â‚ą5,250.00
Mkt Cap Cr
1,76,300.50
P/E
81.77
P/B
20.96
ROA
4.87%
ROE
25.49%
ROCE
13.85%
Quick Ratio
0.75
EV/EBITDA
38.3
Based on fundamentals, this stock's
Step 1 of 5
Performance
Very Poor
Torrent Pharma. has not beaten FD return of 7%
Step 1 of 5
Valuation
Overvalued
Torrent Pharma. appears overvalued compared to its peers
Step 5 of 5
Earnings
Excellent
Torrent Pharma. revenue, operating profit and net profit are growing
Peer Comparison
Peer comparison — key ratios
NameMkt Cap CrP/EP/BROAROEROCEQuick RatioEV/EBITDA
Sun Pharmaceutical Industries4,19,619.6935.035.0811.19%13.74%17.33%2.3121.42
Divis Laboratories2,46,222.1184.1814.6914.6%15.32%19.56%3.556.81
Zydus Lifesciences1,12,817.6824.574.168.57%18.59%17.35%0.9115.07
Laurus Labs1,10,823.44101.6420.9110.38%16.77%16.14%0.6854.71
Cipla1,07,446.7932.023.127.92%11.27%14.95%2.517.97
Dr. Reddy's Laboratories1,03,471.1432.52.725.48%11.07%12.54%1.3516.27
Mankind Pharma96,243.6447.326.07.36%11.74%13.13%0.7426.02
Aurobindo Pharma96,836.1026.12.566.34%9.25%11.76%1.1512.57
Lupin89,628.8316.153.9914.47%23.76%24.88%1.429.46
Glenmark Pharma63,980.3335.596.099.03%28.08%32.7%1.2319.04

Auto-generated based on historical fundamentals; not a recommendation to buy/sell.

About Torrent Pharmaceuticals

ISIN
INE685A01028
Sector Market Cap
â‚ą 176,300.50 Cr

Torrent Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is engaged in research, development, manufacturing, marketing and distribution of branded and generic pharmaceutical formulations in India and internationally. The Company is focused on various therapeutic segments, such as cardiovascular (CV), central nervous system (CNS), gastrointestinal (GI), vitamins minerals nutrients (VMN), anti-diabetes (AD), pain management, gynecology, and dermatology. Its pediatric product brands include Tedibar, Atogla, Spoo and B4 Nappi. Its Anti-diabetic products include Gliclazide 80 mg, Tablets, Gliclazide 30 mg, Tablets, Glimepiride 1, 2, 3, 4 mg, Tablets, and others. Its dermatologic therapy products include Macrotor, Ahaglow S Facewash, Fungicide Lotion, Hairjoy 2%, New Dewsoft Cream, Lookbrite 20GMS, Cortaz NC, Dermanex, and others. Its manufacturing facilities are located in the states of Gujarat, Himachal Pradesh, Madhya Pradesh, Andhra Pradesh and Sikkim.

Torrent Pharmaceuticals Financial Highlights

  • Revenue: Torrent Pharmaceuticals reported revenue of â‚ą13,886.00 crore in FY26 vs â‚ą11,539.00 crore in FY25. It showed an increase of 20.34% on a yearly basis.
  • Operating Profit: Torrent Pharmaceuticals reported an operating profit of â‚ą2,872.00 crore in FY26 vs â‚ą2,673.00 crore in FY25. It showed an increase of 7.44% on a year-on-year basis.
  • Net Profit: Torrent Pharmaceuticals reported a net profit of â‚ą2,138.00 crore in FY26 vs â‚ą1,911.00 crore in FY25. It showed an increase of 11.88% on a yearly basis.

Torrent Pharmaceuticals Quarterly Result Highlights

  • Torrent Pharmaceuticals reported revenue of â‚ą4,909.00 crore in Jun 2026, compared with â‚ą4,180.00 crore in Mar 2026, representing an increase of 17.44% on a quarter-on-quarter (QoQ) basis.
  • Torrent Pharmaceuticals reported an operating profit of â‚ą733.00 crore in Jun 2026, compared with â‚ą529.00 crore in Mar 2026, representing an increase of 38.56% on a quarter-on-quarter (QoQ) basis.
  • Torrent Pharmaceuticals reported a profit of â‚ą566.00 crore in Jun 2026, compared with â‚ą364.00 crore in Mar 2026, reflecting an increase of 55.49% on a QoQ basis.
  • The earnings per share (EPS) of Torrent Pharmaceuticals stood at â‚ą63.92 during Jun 2026.

Data Source: BSE, Company announcements

Securities shown are illustrative, not recommendations. Past performance does not guarantee future results.

Know more
Promoters
60.78%
FII
17.97%
Other DII
4.59%
Retail and other
8.38%
Mutual funds
8.27%
Foreign Institutional Investor (FII)
FII shareholding by period
Dec 202516.13%
Mar 202616.18%
Jun 202615.44%
Jul 202617.97%
1 day
-1.35%
1 week
-2.89%
1 month
-7.76%
1 year
+30.04%
3 years
+141.61%
5 years
+192.61%
Day
Open / Close
Change %
14 Oct 26
â‚ą4,640.00 / â‚ą4,580.00
-1.35%
13 Oct 26
â‚ą4,665.00 / â‚ą4,642.90
-0.84%
12 Oct 26
â‚ą4,657.10 / â‚ą4,682.00
+0.54%
09 Oct 26
â‚ą4,618.00 / â‚ą4,656.90
+0.86%
Show more

Torrent Pharmaceuticals Financials

Full statement

Income Statement · Consolidated

Income Statement · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenueâ‚ą13,979.73â‚ą11,516.09â‚ą10,727.84â‚ą9,620.15
Other Income-â‚ą93.58â‚ą23.27â‚ą57.91â‚ą45.14
Total Revenueâ‚ą13,886.15â‚ą11,539.36â‚ą10,785.75â‚ą9,665.29
Total Expensesâ‚ą10,925.21â‚ą8,842.34â‚ą8,522.02â‚ą7,818.13
Profit Before Taxâ‚ą2,872.19â‚ą2,672.81â‚ą2,352.11â‚ą1,847.16
Taxâ‚ą734.01â‚ą761.56â‚ą695.73â‚ą601.93
Profit After Taxâ‚ą2,138.18â‚ą1,911.25â‚ą1,656.38â‚ą1,245.23
EPS - Basicâ‚ą63.92â‚ą56.47â‚ą48.94â‚ą36.79
EPS - Dilutedâ‚ą63.92â‚ą56.47â‚ą48.94â‚ą36.79

Cash Flow · Consolidated

Cash Flow · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before taxâ‚ą2,872.19â‚ą2,672.81â‚ą2,352.11â‚ą1,847.16
Income before WC changesâ‚ą4,173.60â‚ą3,668.86â‚ą3,346.10â‚ą2,784.40
Change in Assets-â‚ą328.20-â‚ą296.98â‚ą22.11-â‚ą53.29
Change in Liabilities-â‚ą13.77-â‚ą183.95â‚ą395.97â‚ą35.09
Change in WC-â‚ą341.97-â‚ą480.93â‚ą418.08-â‚ą18.20
Cash flow from Operationsâ‚ą3,022.71â‚ą2,585.11â‚ą3,266.08â‚ą2,368.13
Cash flow from Investing-â‚ą12,712.41-â‚ą540.05-â‚ą167.90-â‚ą2,415.31
Cash flow from Financingâ‚ą10,150.60-â‚ą2,297.99-â‚ą2,779.64â‚ą77.36
Total Cash Flowâ‚ą460.90-â‚ą252.93â‚ą318.54â‚ą30.18
Cash (Start of the year)â‚ą573.48â‚ą835.14â‚ą508.53â‚ą398.40
Cash (End of the year)â‚ą1,117.20â‚ą573.48â‚ą835.14â‚ą508.53

Balance Sheet · Consolidated

Balance Sheet · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assetsâ‚ą34,920.07â‚ą9,367.17â‚ą9,449.10â‚ą9,698.13
Current Assetsâ‚ą9,391.89â‚ą5,622.57â‚ą5,611.48â‚ą5,313.72
Total Assetsâ‚ą44,311.96â‚ą14,989.74â‚ą15,060.58â‚ą15,011.85
Current Liabilitiesâ‚ą8,343.33â‚ą4,717.19â‚ą5,425.25â‚ą5,447.30
Net Current Assetâ‚ą1,048.56â‚ą905.38â‚ą186.23-â‚ą133.58
Non-Current Liabilitiesâ‚ą18,383.80â‚ą2,681.86â‚ą2,779.18â‚ą3,366.48
Equity Capitalâ‚ą17,584.83â‚ą7,590.69â‚ą6,856.15â‚ą6,198.07
Total Equity & Liabilitiesâ‚ą44,311.96â‚ą14,989.74â‚ą15,060.58â‚ą15,011.85

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenueâ‚ą10,712.00â‚ą9,682.44â‚ą8,532.90â‚ą7,695.20
Other Incomeâ‚ą17.92â‚ą31.50â‚ą91.36â‚ą81.88
Total Revenueâ‚ą10,729.92â‚ą9,713.94â‚ą8,624.26â‚ą7,777.08
Total Expensesâ‚ą7,763.29â‚ą7,079.55â‚ą6,707.69â‚ą6,200.06
Profit Before Taxâ‚ą2,896.61â‚ą2,610.18â‚ą1,916.57â‚ą1,577.02
Taxâ‚ą705.02â‚ą722.12â‚ą559.49â‚ą525.63
Profit After Taxâ‚ą2,191.59â‚ą1,888.06â‚ą1,357.08â‚ą1,051.39
EPS - Basicâ‚ą64.75â‚ą55.79â‚ą40.10â‚ą31.07
EPS - Dilutedâ‚ą64.75â‚ą55.79â‚ą40.10â‚ą31.07

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before taxâ‚ą2,896.61â‚ą2,610.18â‚ą1,916.57â‚ą1,577.02
Income before WC changesâ‚ą3,912.76â‚ą3,579.68â‚ą2,874.18â‚ą2,567.51
Change in Assets-â‚ą466.77-â‚ą638.12â‚ą212.68-â‚ą51.24
Change in Liabilitiesâ‚ą0.78â‚ą123.05â‚ą130.92â‚ą21.60
Change in WC-â‚ą465.99-â‚ą515.07â‚ą343.60-â‚ą29.64
Cash flow from Operationsâ‚ą2,730.83â‚ą2,574.50â‚ą2,893.10â‚ą2,265.41
Cash flow from Investing-â‚ą12,990.20-â‚ą470.09-â‚ą296.07-â‚ą2,384.07
Cash flow from Financingâ‚ą10,225.23-â‚ą2,104.46-â‚ą2,577.57â‚ą80.74
Total Cash Flow-â‚ą34.14-â‚ą0.05â‚ą19.46-â‚ą37.92
Cash (Start of the year)â‚ą104.81â‚ą104.86â‚ą85.40â‚ą65.00
Cash (End of the year)â‚ą70.67â‚ą104.81â‚ą104.86â‚ą85.40

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assetsâ‚ą20,922.49â‚ą8,492.96â‚ą8,635.53â‚ą8,944.85
Current Assetsâ‚ą4,891.04â‚ą4,348.80â‚ą3,741.06â‚ą3,927.08
Total Assetsâ‚ą25,813.53â‚ą12,841.76â‚ą12,376.59â‚ą12,871.93
Current Liabilitiesâ‚ą4,588.83â‚ą2,979.63â‚ą2,988.60â‚ą3,409.15
Net Current Assetâ‚ą302.21â‚ą1,369.17â‚ą752.46â‚ą517.93
Non-Current Liabilitiesâ‚ą12,772.53â‚ą2,269.63â‚ą2,559.23â‚ą3,006.82
Equity Capitalâ‚ą8,452.17â‚ą7,592.50â‚ą6,828.76â‚ą6,455.96
Total Equity & Liabilitiesâ‚ą25,813.53â‚ą12,841.76â‚ą12,376.59â‚ą12,871.93
* All values are in INR Crore
Qty
Bid
0
0
0
0
0
0
0
0
0
0
Ask
Qty
4580
50
0
0
0
0
0
0
0
0
Bid Total: 0
Ask Total: 50
Buy orders: 0%
Sell orders: 100%
Bearish
2
Neutral
3
Bullish
3
Slightly Bullish
by SEBI experts
Expert Pick
EXPPICK
Stop-loss
Entry price
Target
Indicator
Value
Verdict
RSI (14)
36.88
Neutral
ATR (14)
104.5
Neutral
STOCH(9,6)
15.33
Bullish
STOCH RSI (14)
17.12
Bullish
ADX(9)
41.09
Bearish
UO(9)
54.64
Neutral
ROC(12)
-5.79
Bearish
WillR(14)
-87.4
Bullish
Period
Simple value
Exponential vaue
5D
4663.02
4676.91
10D
4732.04
4726.04
20D
4818.7
4790.64
50D
4896.66
4834.94
100D
4786.14
4750.85
Volume trend — traded volume by day
14 Oct3L
13 Oct1L
12 Oct4L
9 Oct3L
8 Oct2L
Average2L

Technical indicators used here are for indicative purposes only. Kindly do not treat it as an investment or trading advice

Compare against other stocks
Torrent Pharmaceuticals
Pharmaceuticals
Add Stock
Add Another

Torrent Pharmaceuticals Share Price FAQs

Disclaimer: The information on this page, including prices, charts, financials, ratios, and other data, is provided for informational and educational purposes only. It is not investment advice, a research report, or a recommendation or solicitation to buy, sell, or hold any security. Data is sourced from third parties and exchanges, may be delayed, and is not guaranteed to be accurate, complete, or timely. Upstox is not liable for any loss arising from its use.